# A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors

> **NCT03516123** · PHASE1 · COMPLETED · sponsor: **CStone Pharmaceuticals** · enrollment: 18 (actual)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** CS3006

## Key facts

- **NCT ID:** NCT03516123
- **Lead sponsor:** CStone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-14
- **Primary completion:** 2020-06-18
- **Final completion:** 2020-06-18
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03516123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03516123, "A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03516123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*